Promoter holding
64.27%
MP
Multani Pharmaceuticals Limited - Due diligence report
A 360° intelligence report on Multani Pharmaceutical: trust score, financial health, credit view, compliance, directors, growth and distress…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Multani Pharmaceutical — 360° Intelligence Report
Generated from MCA filings & public records84/100
Trust Score
Low Risk
Multani Pharmaceutical is assessed as Low Risk with a Trust Score of 84/100. Multani Pharmaceutical is an active public limited indian non-government company incorporated in 1986, operating in the FMCG sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 02 Aug 2026 from the latest processed filings. Multani Pharmaceuticals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
84/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
66/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Profitable - internal accruals available.
- Externally credit-rated (A3).
Charges position: 5 open (49.85 cr) · 39 satisfied (23.76 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 9 | 48.0 cr |
| Punjab Nationalbank | 1 | 48.0 cr |
| Sidbi | 6 | 48.0 cr |
| Standard Chartered Bank | 1 | 48.0 cr |
| Punjab National Bank | 27 | 48.0 cr |
Compliance Score: 66/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 2 court forum(s).
- Delayed payments to MSME suppliers disclosed (96 disclosure(s)).
- 11 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RAJESH SABHARWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANJAY KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRADEEP MULTANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| YOGESH SAHNI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VINAY RUNGTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 5 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
3
Group entities
3
Capital events
2 allotment(s) · 0 transfer(s)
| Group entity | Relationship | % held |
|---|---|---|
| Nature To Skin Care Private Limited | Subsidiary Company | 74.00% |
| Multani Wellness Private Limited | Subsidiary Company | 74.00% |
| Multani Infra And Agro Private Limited | Subsidiary Company | 74.00% |
| Adm Agrovet Llp | Subsidiary Company | 74.00% |
| Manya Devi Agrovet Llp | Subsidiary Company | 74.00% |
| Sim Man Devi Agro Llp | Subsidiary Company | 74.00% |
| Jmd Asu Agro Llp | Subsidiary Company | 74.00% |
| Njm Agrotech Llp | Subsidiary Company | 74.00% |
| Ajm Agrovet Llp | Subsidiary Company | 74.00% |
| Cinzia Agrotech Llp | Subsidiary Company | 74.00% |
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 90 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Net margin improved to 0.86.
EPFO headcount growing - hiring signal.
Operating for 40+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
5 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 7.94 cr.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence79/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment86/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 5 open charge(s) of 49.85 cr already registered.
- Compliance gaps should be priced into terms.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events17 Nov 2025
Charge created
Sidbi - 2.25 cr
04 Nov 2025
Charge created
Sidbi - 3.00 cr
20 Sep 2025
Charge created
Others - 20.00 cr
03 Apr 2025
Charge satisfied
Others
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
20 Jan 2024
Director ceased
DINESH RASTOGI
19 Jan 2024
Charge created
Others - 1.10 cr
02 Feb 2023
Director ceased
KAMAL PRASAD
01 Feb 2023
Director appointed
SANJAY KUMAR (Director)
Director appointed
VINAY RUNGTA (Director)
18 Jan 2021
Charge created
Sidbi - 1.50 cr
28 Oct 2020
Charge satisfied
Sidbi
31 Mar 2020
Director ceased
RAJESH SABHARWAL
Director ceased
PRADEEP MULTANI
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
5 active director(s) / partner(s); board looks stable and experienced.
11 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 3 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of A3 from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Saraf Chemicals Private Limited | U24100MH1984PTC033486 | Mumbai, Maharashtra, India |
| Dotshot | U24230MH2004PTC149202 | Mumbai, Maharashtra, India |
| Amn Life | U24230MH2003PTC140663 | Mumbai, Maharashtra, India |
| Radiant Indus Chem Private Limited | U15132MH1982PTC026313 | Mumbai, Maharashtra, India |
| Premier Medical Corporation | U24230GJ1996PTC109644 | Sarigam, Gujarat, India |
| Balaji | U24116GJ2002PTC040401 | Sanand, Gujarat, India |
| Embio | U24110MH1986PLC038680 | Mumbai, Maharashtra, India |
| Sicer India Private Limited | U24223GJ2013PTC073283 | Wankaner, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Multani Pharmaceutical before audits and certifications: compliance score 66/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Multani Pharmaceutical: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Multani Pharmaceutical - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 84/100, distress signals and MSME payment-delay disclosures - know whether Multani Pharmaceutical pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Multani Pharmaceutical - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Multani Pharmaceutical an active company?
Multani Pharmaceutical has MCA status “Active” with a compliance score of 66/100 (Moderate).
Is Multani Pharmaceutical financially healthy?
Multani Pharmaceutical has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Multani Pharmaceutical?
Its overall Trust Score is 84/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Multani Pharmaceutical?
See the directors and ownership sections above for board and shareholding detail. 5 active director(s) are on record.
Does Multani Pharmaceutical have loans or charges against its assets?
5 open charge(s) are registered against its assets, and 39 earlier charge(s) stand satisfied.
Is Multani Pharmaceutical up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 66/100 (Moderate).
Is it risky to lend to Multani Pharmaceutical?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
